---
title: "Hengrui Pharma signed a cooperation agreement with the Hong Kong Greater China Cancer Foundation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/267002393.md"
description: "Recently, Hengrui Pharma signed a partnership agreement with the Hong Kong Greater China Cancer Fund in Hong Kong as a caring corporate partner under the NPP program, aiming to provide advanced clinical options for breast cancer patients in Hong Kong who urgently need innovative therapies. According to the agreement, both parties will provide Hengrui Pharma's innovative targeted drug—Pyrotinib Maleate Tablets—to breast cancer patients in Hong Kong public hospitals under the \"Designated Patient Drug Use Program.\""
datetime: "2025-11-22T04:47:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/267002393.md)
  - [en](https://longbridge.com/en/news/267002393.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/267002393.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/267002393.md) | [繁體中文](https://longbridge.com/zh-HK/news/267002393.md)


# Hengrui Pharma signed a cooperation agreement with the Hong Kong Greater China Cancer Foundation

Recently, Hengrui Pharma signed a partnership agreement with the Hong Kong Greater China Cancer Fund in Hong Kong as a caring corporate partner under the NPP program, aiming to provide advanced clinical options for breast cancer patients in Hong Kong who urgently need innovative therapies. According to the agreement, both parties will provide Hengrui Pharma's innovative targeted drug—Pyrotinib Maleate Tablets—to breast cancer patients in public hospitals in Hong Kong under the "Designated Patient Drug Use Program."

### Related Stocks

- [Hengrui Pharma (600276.CN)](https://longbridge.com/en/quote/600276.CN.md)
- [HENGRUI PHARMA (01276.HK)](https://longbridge.com/en/quote/01276.HK.md)

## Related News & Research

- [Hengrui Pharma Unit Gets China Nod for New Indication of Cancer Drug](https://longbridge.com/en/news/279944925.md)
- [Hengrui Pharma Gets Nod to Trial Six Drugs](https://longbridge.com/en/news/271064302.md)
- [Fosun Pharmaceutical's Subsidiary Gets Nod for Phase I Trial for Breast Cancer Drug](https://longbridge.com/en/news/281480931.md)
- [The rise of ADCs in oncology: how antibody drug conjugate therapies deliver precision](https://longbridge.com/en/news/281182503.md)
- [Astellas Speeds Pipeline, Eyes 10 Late-Stage Drugs by 2034](https://longbridge.com/en/news/281117306.md)